BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
June 02, 2024 04:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., June 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence showing that patients with hereditary angioedema...
Fortrea Apresenta Solução Abrangente para Aprimorar a Diversidade e Inclusão na Pesquisa Clínica
May 31, 2024 13:24 ET
|
Fortrea Holdings Inc
DURHAM, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- A Fortrea (Nasdaq: FTRE) (a “Empresa”), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje o lançamento da sua solução...
Fortrea Memperkenalkan Penyelesaian Komprehensif untuk Meningkatkan Kepelbagaian dan Rangkuman dalam Penyelidikan Klinikal
May 31, 2024 13:24 ET
|
Fortrea Holdings Inc
DURHAM, N.C., June 01, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: Fortrea (FTRE) ("Syarikat"), sebuah organisasi penyelidikan kontrak (CRO) global terkemuka, hari ini mengumumkan penyelesaian...
Fortrea Memperkenalkan Solusi yang Komprehensif untuk Meningkatkan Keberagaman dan Inklusi dalam Penelitian Klinis
May 31, 2024 13:24 ET
|
Fortrea Holdings Inc
DURHAM, N.C., June 01, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (“Perusahaan”), organisasi riset berbasis kontrak (CRO) global yang terkemuka, hari ini mengumumkan solusinya yang terintegrasi...
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
May 31, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies...
Humacyte to Present at the Jefferies Global Healthcare Conference
May 30, 2024 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Fortrea Introduces Comprehensive Solution to Improve Diversity and Inclusion in Clinical Research
May 30, 2024 07:00 ET
|
Fortrea Holdings Inc
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced its comprehensive and integrated...
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 30, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Scorpius Holdings Achieves 359% Year-Over-Year Increase in Revenue for the First Quarter of 2024
May 29, 2024 07:00 ET
|
Scorpius Holdings, Inc.
DURHAM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”),...
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
May 29, 2024 07:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...